The science behind Souvenaid®
Souvenaid® is proven to slow memory and cognitive decline by 60% in an early stage of Alzheimer’s disease known as mild cognitive impairment when taken daily over 3 years.1
Additional results from this 3-year LiPiDiDiet clinical trial:
- Souvenaid use reduced brain shrinkage by 33% over the 3 year period1
- Souvenaid use reduced the loss of everyday task performance by 45% over the 3 year period1
With 20 years of evidence-based research, Souvenaid® has been proven to support memory function when initiated in the early stages of Alzheimer’s disease.
An independent study funded by the European Commission investigated the long-term use and impact of Souvenaid® on memory and cognitive function in the very early stages of Alzheimer’s disease, including mild cognitive impairment. This study was called the LiPiDiDiet study.1-3
The study investigators concluded that patients in this clinical trial who drank one bottle of Souvenaid® daily for 3 years had less decline in their memory and thinking skills than those who were not on Souvenaid®. These patients also had less brain shrinkage, particularly in the area of the brain known as the hippocampus which is responsible for memory.
These are the key results from the LiPiDiDiet 3 year study for patients who were taking Souvenaid® once daily for 3 years:
✔ Slowed the progression of memory and cognitive decline by 60%
✔ Reduced brain shrinkage by 33%
✔ Reduced the loss of everyday task performance by 45%
The study confirms the benefit of starting daily Souvenaid® early in Alzheimer’s disease and shows that benefits can be sustained over 3 years.
Souvenaid’s® effect on memory function has also been shown in two earlier clinical trials, in patients with early Alzheimer’s disease taking Souvenaid® once daily over 12 and 24 weeks, respectively2,3.
What if I still have questions?
If you feel that you still have questions, please take a look at our Frequently Asked Questions, send us an email or call our Souvenaid® team on 1800 319 420.
- Soininen H, Solomon A, Visser PJ, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimer’s Dement. 2020;1–12.
- Scheltens P et al. Alzheimers Dement 2010; 6: 1–10.e1.
- Scheltens P et al. J Alzheimers Dis 2012; 31: 225–236
Souvenaid® is a Food for Special Medical Purpose for the dietary management of early Alzheimer’s disease. Must be used under medical supervision.